HOME >> BIOLOGY >> NEWS
Females more prone to brain damage from alcohol abuse

PORTLAND, Ore. - Alcoholism has traditionally been considered a male disease because there are many more alcoholic males than females.

But a new study by researchers at Oregon Health & Science University and the Portland Veterans Affairs Medical Center suggests that women are more prone to brain damage from alcohol abuse than men.

The study led by Kristine Wiren, Ph.D., associate professor of behavioral neuroscience and medicine, OHSU School of Medicine, and research biologist, PVAMC Research Service, found that female mice are more susceptible to neurotoxic effects of alcohol withdrawal, including significantly increased brain cell death, than male mice. It also found the gender difference exists whether the animals are prone to severe withdrawal due to a genetic predisposition, or resistant to it.

Wiren said she was surprised by the results.

"We designed the experiment to be able to identify gene expression differences between lines of mice that are genetically selected for severe alcohol withdrawal compared with mice that are resistant to alcohol withdrawal," Wiren said. "I thought there would be a difference between the genders, but I didn't think it would be the most important thing."

She added, "The withdrawal severity phenotypes do show some differences, but they're subtle."

The study appears in the online edition of the journal Neuropsychopharmacology.

Wiren and Joel Hashimoto, research associate of behavioral neuroscience at OHSU and the PVAMC Research Service, examined four groups of selectively bred mice: two female groups, including one prone to severe withdrawal and one resistant to severe withdrawal, and two similar male groups. Four control groups also were used.

Using DNA microarray or "gene chip" analysis, a laboratory process involving advanced robotics that allows large numbers of genes and their complex interactions to be observed, Wiren and Hashimoto examined 5,00
'"/>

Contact: Jonathan Modie
modiej@ohsu.edu
503-494-8231
Oregon Health & Science University
25-Jul-2007


Page: 1 2 3

Related biology news :

1. Females do best if they wait a while
2. Females, alcohol and hormones
3. Accident-prone? Scientists link brain function to knee injuries
4. Bernese Mountain Dogs prone to Borrelia burgdorferi infection
5. Children of allergy sufferers prone to same problem
6. Man, chimp difference may have made us prone to cancer
7. By age 6, children of overweight mothers are also prone to obesity
8. Invasion of the brain tumors
9. Preclinical study links gene to brain aneurysm formation
10. Gene variant is associated with brain anatomy, clinical course of ADHD
11. Human knowledge is based upon directed connectivity between brain areas

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Females more prone brain damage from alcohol abuse

(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... 2015 Veolia’s environmental monitoring technology ... American distribution agreement with VWR to distribute TECTA™ ... more than 160 years of experience, VWR, a ... laboratory and production facilities, has cultivated a value ... services to enable science. Endetec’s TECTA™ B16, ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
(Date:5/20/2015)... -- Health eCareers, the healthcare industry,s online career hub, ... looking for the flexibility of short-term assignments through ... tool dedicated exclusively to temporary and shift work ... employers to quickly find and hire experienced professionals ... other temporary positions, eliminating the time and resources ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
Cached News: